Ok Let's try to clear this up as far as the amount of spending towards R&D is concerned and why it appears to be "ridiculously low". FELLER you are absolutely right about the incentives offered to the OWCP doctors and research team as one way of keeping the costs down. Triple9 you are absolutely wrong, and reckless I might add, in making the statement that the "amounts and ratios are a red flag".

For the others here that might have thought the same thing, the amount spent on R&D is low for a reason. They are not a sign of a red flag!!!! Read the 10-Q and the 10-K and for that matter other reports that have been filed. You keep coming across the term "Collaboration Agreements". With regards to R&D the principal Collaborator is Sheba Academic Medical Center. If it were not for relinquishing some of the intellectual property rights to Sheba, the fees paid to them would be much much higher. I think this is a smart way of keeping costs down. Give management credit.

While we retain full ownership on our intellectual property rights that we conceived prior to the signing of the research collaboration and license agreements with Sheba Academic Medical Center, the psoriasis and fibromyalgia agreements with Sheba provide that all intellectual property rights that is conceived during the course of the research is to be jointly owned by Sheba and One World Cannabis.

With all due respect, please read the reports and try to put two and two together before you and others make statements that can be taken the wrong way and serve no purpose other than to give people with different agendas the opportunity to capitalize and buy shares at a cheap price.